Boston Scientific signs agreement to divest BTG Specialty Pharmaceuticals business
SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases. “This transaction will help